Psyence Biomedical Ltd

NAS:PBM (Canada)  
$ 0.83 +0.0028 (+0.34%) 10:08 PM EST
At Loss
Market Cap:
$ 11.10M
Enterprise V:
$ 11.23M
Volume:
90.99K
Avg Vol (2M):
322.18K
Volume:
90.99K
At Loss
Avg Vol (2M):
322.18K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Psyence Biomedical Ltd ( ) from 2024 to May 27 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Psyence Biomedical stock (PBM) PE ratio as of May 27 2024 is 0. More Details

Psyence Biomedical Ltd (PBM) PE Ratio (TTM) Chart

To

Psyence Biomedical Ltd (PBM) PE Ratio (TTM) Historical Data

Total 85
  • 1
Psyence Biomedical PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-05-28 At Loss 2024-03-27 At Loss
2024-05-24 At Loss 2024-03-26 At Loss
2024-05-23 At Loss 2024-03-25 At Loss
2024-05-22 At Loss 2024-03-22 At Loss
2024-05-21 At Loss 2024-03-21 At Loss
2024-05-20 At Loss 2024-03-20 At Loss
2024-05-17 At Loss 2024-03-19 At Loss
2024-05-16 At Loss 2024-03-18 At Loss
2024-05-15 At Loss 2024-03-15 At Loss
2024-05-14 At Loss 2024-03-14 At Loss
2024-05-13 At Loss 2024-03-13 At Loss
2024-05-10 At Loss 2024-03-12 At Loss
2024-05-09 At Loss 2024-03-11 At Loss
2024-05-08 At Loss 2024-03-08 At Loss
2024-05-07 At Loss 2024-03-07 At Loss
2024-05-06 At Loss 2024-03-06 At Loss
2024-05-03 At Loss 2024-03-05 At Loss
2024-05-02 At Loss 2024-03-04 At Loss
2024-05-01 At Loss 2024-03-01 At Loss
2024-04-30 At Loss 2024-02-29 At Loss
2024-04-29 At Loss 2024-02-28 At Loss
2024-04-26 At Loss 2024-02-27 At Loss
2024-04-25 At Loss 2024-02-26 At Loss
2024-04-24 At Loss 2024-02-23 At Loss
2024-04-23 At Loss 2024-02-22 At Loss
2024-04-22 At Loss 2024-02-21 At Loss
2024-04-19 At Loss 2024-02-20 At Loss
2024-04-18 At Loss 2024-02-16 At Loss
2024-04-17 At Loss 2024-02-15 At Loss
2024-04-16 At Loss 2024-02-14 At Loss
2024-04-15 At Loss 2024-02-13 At Loss
2024-04-12 At Loss 2024-02-12 At Loss
2024-04-11 At Loss 2024-02-09 At Loss
2024-04-10 At Loss 2024-02-08 At Loss
2024-04-09 At Loss 2024-02-07 At Loss
2024-04-08 At Loss 2024-02-06 At Loss
2024-04-05 At Loss 2024-02-05 At Loss
2024-04-04 At Loss 2024-02-02 At Loss
2024-04-03 At Loss 2024-02-01 At Loss
2024-04-02 At Loss 2024-01-31 At Loss
2024-04-01 At Loss 2024-01-30 At Loss
2024-03-28 At Loss 2024-01-29 At Loss

Psyence Biomedical Ltd (PBM) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Psyence Biomedical Ltd
NAICS : 541715 SIC : 3741
ISIN : CA74449F1009
Compare
Compare
Traded in other countries / regions
PBM.USA
IPO Date
2024-01-26
Description
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.